All articles tagged with #life sciences
Anthropic unveiled Claude Science, an AI workbench for scientists, and signaled plans to develop its own drugs—targeting neglected diseases—while continuing to sell AI tools to biotech and pharma customers. Experts say AI can accelerate drug discovery but human oversight, data gaps, and regulatory hurdles mean any AI-designed drug is likely years away.
Anthropic says it will start developing its own drugs using Claude Science to gain hands-on experience applying its AI to real biotech problems, with unclear plans for commercialization.
Merck KGaA, Darmstadt, Germany, agreed to acquire Bio-Techne for US$73 per share in cash, valuing the deal at about US$11.3 billion (EUR 9.9 billion) and delivering a 36% premium to Bio-Techne’s one-month VWAP. The transaction is expected to be immediately accretive to EBITDA margins and revenue growth, with EPS accretion by year three after closing. Bio-Techne’s multi-omics, spatial biology, analytical technologies and cell-therapy capabilities would extend Merck KGaA’s life-science footprint from discovery through manufacturing, delivering roughly €140 million in annual cost synergies by year three. Financing will come from cash on hand and new debt, with closing targeted for late 2026 or early 2027, subject to customary approvals and shareholder consent.
Life sciences lab real estate is clawing back from disaster, signaling renewed demand and potential opportunities for investors as the market stabilizes.
Philanthropists Michael and Susan Dell pledged $750 million to establish a life sciences hub, a landmark gift intended to accelerate biomedical research, biotech innovation, and related workforce development.
Michael and Susan Dell committed more than $1 billion to UT Austin to establish the UT Dell Campus for Advanced Research and the UT Dell Medical Center, uniting medicine, life sciences and AI-enabled computing with MD Anderson as a partner. The gift funds undergraduate scholarships, housing, and the Texas Advanced Computing Center, positions Texas as a life sciences hub, and supports a broader $10 billion fundraising goal over 10 years; the medical center is slated to open in 2030 with groundbreaking planned this year.
OpenAI launches GPT-Rosalind, a life sciences-focused AI model designed to accelerate research in genomics and biochemistry by synthesizing evidence and generating hypotheses, while keeping humans in the loop; it features enterprise-grade security and is being rolled out in a research preview to trusted customers (e.g., Amgen, Moderna, Allen Institute, Thermo Fisher) to speed health outcomes and drug discovery without replacing scientists, amid concerns about misuse.
OpenAI unveiled a life-sciences-focused AI model, GPT-Rosalind, aimed at the biopharma market and positioned to compete with Anthropic as tech giants push into pharma AI.
Blackstone has closed a record $6.3 billion life sciences investment fund, the largest ever for a private fund in the sector, underscoring strong investor demand for biotech opportunities.
New Haven received a $50.5 million state grant to support the development of a new life sciences building, quantum computing initiatives, and pedestrian-friendly infrastructure, aiming to boost scientific research, job creation, and economic growth in the city.
OpenAI collaborated with Retro Bio to develop GPT‑4b micro, a specialized AI model for protein engineering, which has successfully accelerated research in stem cell reprogramming and DNA repair, demonstrating significant improvements over traditional methods and promising advancements in regenerative medicine.
Veeva Systems' stock surged 22% after beating Q1 earnings forecasts and raising fiscal-year guidance, driven by strong financial results and expansion plans beyond the life sciences sector, though some analysts remain cautious due to industry pressures.
Danaher Corporation reported its third-quarter 2023 results, with net earnings of $1.1 billion and revenues of $6.9 billion, representing a 10.5% decrease year-over-year. The company's non-GAAP adjusted diluted net earnings per common share were $2.02. Danaher's Biotechnology segment performed as expected, while higher respiratory testing revenue offset slightly softer demand in Life Sciences. The company also completed the spin-off of Veralto Corporation and provided its outlook for the fourth quarter and full year 2023, anticipating a decline in non-GAAP base business core revenue.
Thermo Fisher Scientific has announced its plans to acquire Olink Holding AB in a $3.1 billion deal, aiming to enhance its life sciences portfolio and support drug discovery. The acquisition will provide Thermo Fisher's biotech customers with advanced protein analysis products and services, aiding in the acceleration of scientific breakthroughs. Olink's U.S.-listed shares surged by nearly 67% following the announcement, while Thermo Fisher's shares declined over 1%. The deal is expected to be completed by mid-2024 and will be funded through cash on hand and debt financing.
Thermo Fisher Scientific, a global leader in scientific services, has announced its plan to acquire Olink Holding AB, a provider of next-generation proteomics solutions, for approximately $3.1 billion. The acquisition will enhance Thermo Fisher's capabilities in the high-growth proteomics market, complementing its existing life sciences and mass spectrometry offerings. Olink's proprietary technology, Proximity Extension Assay (PEA), enables rapid and efficient protein analysis, and the company has a library of over 5,300 validated protein biomarker targets. The transaction is expected to be completed by mid-2024, subject to regulatory approvals.